Efficacious Intermittent Dosing of a Novel JAK2 Inhibitor in Mouse Models of Polycythemia Vera

A high percentage of patients with the myeloproliferative disorder polycythemia vera (PV) harbor a Val617→Phe activating mutation in the Janus kinase 2 (JAK2) gene, and both cell culture and mouse models have established a functional role for this mutation in the development of this disease. We desc...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Kraus, Manfred, Wang, Yuxun, Aleksandrowicz, Dan, Bachman, Eric, Szewczak, Alexander A., Walker, Deborah, Xu, Lin, Bouthillette, Melaney, Childers, Kaleen M., Dolinski, Brian, Haidle, Andrew M., Kopinja, Johnny, Lee, Linda, Lim, Jongwon, Little, Kevin D., Ma, Yanhong, Mathur, Anjili, Mo, Jan-Rung, O’Hare, Erin, Otte, Ryan D., Taoka, Brandon M., Wang, Wenxian, Yin, Hong, Zabierek, Anna A., Zhang, Weisheng, Zhao, Shuxia, Zhu, Joe, Young, Jonathan R., Marshall, C. Gary
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Public Library of Science 2012
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3356383/
https://ncbi.nlm.nih.gov/pubmed/22623993
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0037207
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak